Search Results
Your search for this matches 25372 pages
Showing 22501 - 22550Cost vs Our Values in Cancer Care
An 80-year-old patient with metastatic prostate cancer asked me to discontinue his treatments, which were costing him more than $1,000 every 3 months. Although he had Medicare, he did not have secondary insurance. I told him that I would seek compassionate-care payment from the pharmaceutical...
AACR Launches New Funding Initiative to Promote Innovative Research From Young Investigators
The American Association for Cancer Research (AACR) is pleased to announce the launch of the AACR NextGen Grants for Transformative Cancer Research, a new funding initiative to stimulate highly innovative research from young investigators. This new grant mechanism is intended to promote and...
The Importance of Including Adolescents and Young Adults With Cancer in Their Advance Care Planning
Three years ago, a study of adolescents and young adults aged 16 to 28 with metastatic or recurrent cancer or HIV/AIDS compared the usefulness of two previously developed advance care planning guides—one prepared specifically for adolescents and young adults and one specifically for adults. The...
A Lasting Legacy
When Emil J Freireich, MD, retires from the University of Texas MD Anderson Cancer Center on September 1, he will have spent 50 years at the institution and a total of 60 years in the pursuit of curing childhood leukemia as well as other cancers and in the educational development of young...
CancerCare Announces National Study: Patient Access and Engagement Report
CancerCare, a national nonprofit organization that provides free psychosocial support, education, and financial assistance to anyone affected by cancer, has announced the launch of a bold, new research initiative. Through surveys among a nationally representative sample of thousands of people with...
Timothy L. Lash, DSc, MPH, Named Head of Winship’s Cancer Prevention and Control Program
Winship Cancer Institute of Emory University has named Timothy L. Lash, DSc, MPH, Professor of Epidemiology in the Rollins School of Public Health and Winship member, as the new Leader for the Winship Cancer Prevention and Control (CPC) Research Program. His position takes effect immediately....
2015 Class of Pew–Stewart Scholars for Cancer Research Announced
The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced the newest class of Pew–Stewart scholars for cancer research on June 11. Five standout scientists, nominated by the country’s leading cancer research institutions, will receive 4 years of flexible funding to pursue...
Michael Allen Pulsipher, MD, Joins Children’s Hospital Los Angeles
Michael Allen Pulsipher, MD, joined the Children’s Center for Cancer and Blood Diseases and the Division of Hematology, Oncology, and Blood and Marrow Transplantation at Children’s Hospital Los Angeles (CHLA) as Head of the Section of Blood and Marrow Transplantation (BMT) and as BMT Clinical...
American College of Physicians Releases High Value Care Screening Advice for Five Common Cancers
In a paper published in Annals of Internal Medicine1, the American College of Physicians (ACP) issued advice for screening average risk adults without symptoms for five common cancers: breast, colorectal, ovarian, prostate, and cervical. In a companion piece also published in Annals2, ACP outlined...
Community Oncologist Stephen Grubbs, MD, to Lead ASCO’s New Clinical Affairs Department
Stephen S. Grubbs, MD, a community oncologist and managing partner at Medical Oncology Hematology Consultants, PA, in Newark, Delaware, has been named the Senior Director of ASCO’s new Clinical Affairs department. Dr. Grubbs is a longtime ASCO member and volunteer and the Principal Investigator of...
Summer Travel: Help Your Patients Understand Why Getting Medical Clearance is Important
Direct your patients to www.cancer.net/blog to get important information on traveling with cancer, including getting medical clearance before they book their flight. This information includes questions to ask the doctor, how to get permission from the airline to fly, and information on packing...
2015–2016 ASCO President Julie M. Vose, MD, MBA, FASCO: Leading During a Year of Historic Changes
Julie M. Vose, MD, MBA, FASCO, began her term as the 2015–2016 President of ASCO at the 2015 Annual Meeting on June 1, 2015. Dr. Vose, a leading expert in the treatment of patients with lymphoma, is the current Neumann M. and Mildred E. Harris Professorial Chair and Chief of the Oncology/Hematology ...
Collective Wisdom: Patient-Centered Care and Research
In 1964, when the first seven physicians who founded ASCO met, I doubt they imagined what a successful Society they were forming. At that time, cancer treatments were just beginning to have some early successes with a few cytotoxic therapies, new radiation modalities, and improved surgical...
Blame
The following essay by Karen J. Krag, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. It is easier ...
The Human Heart: Tales of Science and Mystery
BOOKMARK Title: The Man Who Touched His Own Heart: True Tales of Science, Surgery, and Mystery Author: Rob Dunn Publisher: Little, Brown and Company Publication date: February 3, 2015 Price: $27.00; hardcover, 384 pages No part of the human anatomy has been as mythologized, analogized, and...
An Oncologist’s Memoir
BOOKMARK Title: Megalies: A Memoir Author: Lodovico Balducci, MD Publisher: Resource Publications Publication date: February 28, 2014 Price: $33.00; hardcover, 304 pages Reading a good book produces various sensory responses; a skilled author exerts his or her narrative power on each page,...
Using Gene Analytics to Identify Patients at Risk for Treatment Toxicity
Genomic applications are now an accepted part of oncologic science and practice. Differences in gene expression have been used to understand and predict tumor behaviors and response to treatment. And now it seems likely that genomics may also play a pivotal role in guiding treatment preferences by...
Stephen Szabo, MD, Named Director of Community Oncology at Winship Cancer Institute
Emory Saint Joseph’s Hospital announced Stephen Szabo, MD, as the new Director of Community Oncology at the hospital’s Winship Cancer Institute. The new program combines the best aspects of community and academic oncology by providing seamless patient care within one medical system. “This is a...
St. Jude to Receive $12 Million in Grants From NIH
Investigators at St. Jude Children’s Research Hospital have received grants totaling more than $12 million from the National Institutes of Health’s (NIH) Pharmacogenomics Research Network (PGRN) for a new Center for Precision Medicine in Leukemia and for the Clinical Pharmacogenetics Implementation ...
Jimmie C. Holland, MD, Receives ‘Woman of Influence’ Award
Earlier this spring, the T.J. Martell Foundation, which supports research in leukemia, other cancers, and AIDS, announced the honorees of its 2015 Women of Influence Awards, which celebrate the achievements of outstanding women in a variety of fields. Among this year’s seven recipients was Jimmie...
Past President of ASCO Takes on New Role at Memorial Sloan Kettering Cancer Center to Improve Patient Care and Public Health
In June, Memorial Sloan Kettering Cancer Center (Memorial) in New York announced it had appointed Clifford A. Hudis, MD, FACP, Chief of Breast Medicine Service, to a newly created position of Vice President for Government Relations and Chief Advocacy Officer. In addition to his new role, Dr. Hudis ...
Comparing Regimens Guides Therapeutic Decisions in Previously Treated Advanced Breast Cancer
Kaufman and colleagues recently reported findings of a phase III trial comparing eribulin (Halaven) vs capecitabine in patients with advanced breast cancer who had previously received anthracycline and taxane therapy,1 and a review of their study appears in this issue of The ASCO Post. Although...
No Survival Benefit for Eribulin vs Capecitabine in Advanced Breast Cancer
Eribulin (Halaven) currently is indicated in the United States for treatment of patients with metastatic breast cancer who previously received at least two chemotherapy regimens for metastatic disease and an anthracycline and a taxane in either the adjuvant or metastatic setting. Its approval was...
ODAC Discussion ‘Constructive’ About Necitumumab for Squamous NSCLC
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) favored the approval of necitumumab in combination with gemcitabine and cisplatin for use in first-line treatment of patients with locally advanced or metastatic squamous non–small cell lung cancer (NSCLC). In...
Magnetic Resonance Imaging/Ultrasound Fusion: A Promising Technology for Image-Guided Prostate Biopsy
An elegant study by Siddiqui et al1—reviewed in this issue of The ASCO Post—offers compelling evidence for the diagnostic utility of “targeted” prostate biopsy using multiparametric magnetic resonance imaging (MRI) data fused with ultrasound images. The technique involves first performing a...
Magnetic Resonance Imaging/Ultrasound Fusion–Guided Biopsy Improves Detection of High-Risk Prostate Cancer
In a study reported in JAMA, M. Minhaj Siddiqui, MD, currently of the University of Maryland School of Medicine, and colleagues found that targeted magnetic resonance imaging (MRI)/ultrasound fusion–guided prostate biopsy increased diagnosis of high-risk prostate cancer and reduced detection of...
Study Shows Current Blood Cancer Drug Prices Are Not Justified
The costs associated with cancer drug prices have risen dramatically over the past 15 years, a trend concerning to many oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center concluded the majority of existing treatments for hematologic cancers are...
The Value Proposition in Oncology: ASCO Session Weighs Points of View
The value proposition in health care is often represented with the following equation: Value = Outcomes/Cost. The simplicity of this equation, however, belies the complexity of its parts, which are the contributions of multiple stakeholders with unique perspectives. A session presented at the 2015...
Glioblastoma: Novel Immunotherapy Approaches Generate Responses and Excitement
Checkpoint inhibitors were major attention grabbers at the 2015 ASCO Annual Meeting, but studies suggested there are other encouraging means of harnessing the immune system in the treatment of glioblastoma. EGFRvIII-Targeted Vaccine David A. Reardon, MD, Clinical Director of the Center for...
Is Proton-Beam Therapy Facing a Difficult Future?
Health-care experts are questioning whether proton-beam therapy is on the verge of an economic bubble—ie, a rapid surge in growth for the industry beyond its intrinsic value, inevitably leading to a drastic drop in earnings for proton centers when the “bubble bursts.” A proton-beam facility can...
Value: What Do We Mean, Who Should Decide?
Oscar Wilde famously defined a cynic as “a man who knows the price of everything and the value of nothing.” I do not think that oncologists need to be as cynical as this, but it was very appropriate that a major theme of this year’s ASCO Annual Meeting was the concept of “value.” It is clear that...
Expert Point of View: Peter B. Bach, MD, MAPP, and Leonard Saltz, MD
Peter B. Bach, MD, MAPP, Director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center (Memorial), New York, discussed Dr. Schrag’s study at the ASCO Health Services Research and Quality of Care session. “Dr. Schrag’s analysis could have been ‘back of the...
Bevacizumab More Cost-Effective Than Cetuximab in Metastatic Colorectal Cancer
The landmark CALGB/SWOG 80405 trial concluded that bevacizumab (Avastin) and cetuximab (Erbitux) provide comparable benefit in the treatment of metastatic colorectal cancer. However, in terms of cost, bevacizumab was recently declared the winner. In an economic analysis presented at the 2015 ASCO...
Collaboration Between Surgeons and Medical Oncologists Improves Outcomes for Patients With Stage III Colon Cancer
Collaboration between surgeons and medical oncologists “is associated with lower mortality without increased cost among patients with stage III colon cancer,” according to a study by Tanvir Hussain, MD, MSc, and colleagues from Johns Hopkins University School of Medicine, Baltimore, and the...
Expect Questions About Increased Risk of Melanoma From Consuming Grapefruits and Orange Juice
Could too much citrus cause skin cancer?” was the lead-in of an NBC News item about a study linking consumption of grapefruits and oranges to an increased risk of melanoma.1 “Citrus consumption and skin cancer: How real is the link?” was the question posed by a headline in The Washington Post.2...
Public Urged Not to Overreact to Study Finding Link Between Citrus Fruits and Melanoma Risk
A study finding a link between citrus consumption and increased risk of melanoma1 may provide food for thought about the findings and implications as well as whet the appetite for more evidence, but according to several experts commenting on the study, it does not mean you should stop eating citrus ...
American University of Beirut Appoints Its 16th President, Fadlo R. Khuri, MD
The American University of Beirut (AUB) recently announced Fadlo R. Khuri, MD, as the 16th President of the University. Dr. Khuri is presently Professor and Chairman of the Department of Hematology and Medical Oncology, Emory University School of Medicine, and holds the Roberto C. Goizueta...
Karen Reckamp, MD, MS, Named Medical Director for Clinical Research Operations at City of Hope
Medical oncologist and lung cancer researcher Karen Reckamp, MD, MS, has been named Medical Director for Clinical Research Operations at City of Hope. In this newly created position, Dr. Reckamp will expand her current role as Chair of the Cancer Protocol Review and Monitoring Committee, in which...
John M. Cunningham, MD, to Chair Pediatrics at the University of Chicago
John M. Cunningham, MD, the Donald N. Pritzker Professor and Interim Chair of the Department of Pediatrics at the University of Chicago, has been formally appointed Chair of the department. An authority on the study and treatment of childhood cancers, as well as the biology and therapy of...
Microangiopathic Hemolytic Anemia and Thrombocytopenia: Answers From Hematology Expert Review Questions
Question 1: What is the best first step in management of this patient? Correct Answer: C. Start plasma exchange. Expert Perspective Although distinguishing among thrombotic thrombocytopenic purpura, typical hemolytic uremic syndrome, and atypical hemolytic uremic syndrome (see Table 1 in the...
Microangiopathic Hemolytic Anemia and Thrombocytopenia: Questions
Hematology Expert Review is an occasional feature that includes a case report followed by questions, answers, and expert commentary. In the July 25 issue of The ASCO Post, part 1 of a case report was published and focused on diagnosis (see summary below). Here, in part 2, the management of this...
Strengthening the Doctor-Patient Relationship: An Interview With Lidia Schapira, MD, FASCO
Earlier this summer, Lidia Schapira, MD, FASCO, a medical oncologist at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, was named Editor-in-Chief of Cancer.Net, ASCO’s patient information website. Prior to taking on this role, Dr....
Obesity and Cancer Bundle: Oncology Provider Guides and Patient Booklets
Many cancer care providers struggle with addressing the topics of weight loss and weight management with their patients. Obesity and Cancer: A Guide for Oncology Providers is a tool that will help oncology providers integrate strategies for weight loss into their practices by offering practical...
Conquer Cancer Foundation Donor Spotlight: Ludwig Cancer Research
Among the Conquer Cancer Foundation’s newest supporters, Ludwig Cancer Research is an international community of distinguished scientists dedicated to preventing and controlling cancer. Its emphasis on collaboration and long-term support has fostered its role as a leader in immunotherapy and other...
New Symposium Brings Together Oncologists and Primary Care Providers to Advance Survivorship Care and Research
With two-thirds of Americans now living at least 5 years after a cancer diagnosis, there are currently 14.5 million cancer survivors living in the United States. By 2024, that number is expected to increase by nearly 25%.1 Although the growing number of survivors is a welcome sign of progress, this ...
Sonidegib in Basal Cell Carcinoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On July 24, 2015, sonidegib (Odomzo) was approved for treatment...
Johnson & Johnson Creates Independent Bioethics Panel to Evaluate Compassionate Drug Use Requests
In May 2015, Johnson & Johnson announced its partnership with New York University (NYU) School of Medicine in New York to create a first-of-its kind independent bioethics panel to review requests made to the company for compassionate use of an investigational drug and determine how the company...
15th Annual Conference of the International Society of Geriatric Oncology (SIOG)
Join the best minds in Geriatric Oncology during the 15th SIOG Annual Conference taking place in Prague, Czech Republic, on November 12–14, 2015. The 3-day scientific program of SIOG 2015 will have the theme: “Geriatric Oncology and Supportive Care: A Global Approach to Advance the Science.” ...
Geriatric Oncology: A Geriatrician’s Perspective
“The management of older individuals, including older cancer patients, involves a wisdom developed over a lifetime, thanks to time-consuming listening and painstaking collection and interpretation of clinical details.” —Lodovico Balducci, MD It is not simple to be a geriatrician in a world of...
Clinical Trials Actively Recruiting Patients With Genitourinary Cancers
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with genitourinary cancers—prostate, bladder, uterine, and testicular. The trials are investigating genetic biomarkers of cancer; proton beam therapy; allogeneic bone marrow...
